Marc Duey - Jun 20, 2024 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: Director
Signature: /s/ John Hamill, as Attorney-in-Fact
Stock symbol: APRE
Transactions as of: Jun 20, 2024
Transactions value $: $0
Form type: 4
Date filed: 6/21/2024, 04:15 PM
Previous filing: Aug 24, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APRE	Common Stock	Award	$0	+1.05K	+0.5%	$0.00	210K	Jun 20, 2024	Direct	F1
holding	APRE	Common Stock						602	Jun 20, 2024	By Spouse	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APRE	Stock Options (Right to Buy)	Award	$0	+4.19K		$0.00	4.19K	Jun 20, 2024	Common Stock	4.19K	$4.07	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F2	The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission th at the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
F3	The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.